Treatment Effect of Type 2 Diabetes Patients in Outpatient Department Based on Blockchain Electronic Mobile Medical App

As the pace of people’s lives accelerates, there are more and more diabetic patients. This research mainly explores the treatment effect of type 2 diabetic patients based on blockchain electronic mobile medical app. Considering that it is more realistic to adopt an off-chain storage solution, the blockchain-based medical data sharing platform in this study adopts an off-chain storage solution. Only key information is stored in the blockchain network, and all medical data will be in the cloud space. For storage, cloud storage uses Aliyun’s OSS storage service, which can be expanded infinitely. The cloud operation module is responsible for all operations that interact with cloud storage. The chain code can call the cloud operation module to upload the user’s encrypted medical data and user ID to Alibaba Cloud’s OSS. The chain code will return the storage address of the medical data and the authorized access address is sent to the blockchain network for consensus on the chain. The message processing module provides information processing functions such as chat information processing, APP use reminders, and health tips. The indicator recording module includes indicator recording functions including 6 indicators of blood sugar, medication, diet, weight, exercise, and sleep. The main function of the indicator analysis module is to display the curve trends of the 6 indicators recorded by the patient in three days, one week, and one month. Comparing the change range of the mean value of glycosylated hemoglobin at the beginning and end of the two groups of patients, it can be found that the change range of glycosylated hemoglobin in the intervention group is −6.04%, while the change range of the control group is only −3.26%. The impact of the mobile medical app designed in this study will indeed be reflected in the patient’s blood sugar control and help patients to better control blood sugar.

Download Full-text

COMPARATIVE STUDY OF ORAL HYPOGLYCEMIC AGENTS IN TYPE-2 DIABETES OBESE PATIENTS

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2018.v11i6.25264 ◽

2018 ◽

Vol 11 (6) ◽

pp. 505

Author(s):

Venkateswarlu Konuru ◽

Ram Mohan Reedy T

Keyword(s):

Blood Sugar ◽

Adverse Drug Reactions ◽

Glycosylated Hemoglobin ◽

Dipeptidyl Peptidase ◽

Hypoglycemic Agents ◽

Diabetic Patients ◽

Drug Reactions ◽

Oral Hypoglycemic Agents ◽

Peptidase Inhibitors

Objectives: The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-2 diabetic patients. The objectives are to compare fasting and postprandial blood sugar (PPBS) levels, to compare body mass index (BMI) in all the groups, and to identify glycosylated hemoglobin levels and adverse drug reactions (if present) in all the groups.Method: This is a prospective observational study conducted in care diabetic center over a period of 1 year. All the patients those are receiving only oral hypoglycemic agents continuously over a period of 3 months and BMI ≥30 were enrolled. The patients receiving insulin were excluded. Patients were followed over a period of 3 months and were reviewed on visit basis (every 30 days). All the necessary information was collected into the data collection form that includes demographic details (age, gender, etc.), past medication history, current treatment charts, and their relevant laboratory reports (fasting blood sugar levels [mg/dl], PPBS levels [mg/dl], glycosylated hemoglobin A1c [HbA1c] (%), and BMI [kg/m2]). Results: A total of 395 patients were recruited into the study and the drugs received by the population were found to be metformin+sulfonylureas (33%), metformin+pioglitazone (26%), and metformin+dipeptidyl peptidase inhibitors (DPI) (23%). A significant reduction in HbA1c was seen in all groups of patients. Adverse drug reactions observed were hypoglycemia, pedal edema, and itching distributed to drugs metformin+DPI, respectively. A significant reduction in BMI was seen in patients receiving DPI and BMI was found to be increased in other groups of patients.Conclusion: Overall, three classes of drugs were found to have similar efficacy. Sulfonylureas were commonly associated with hypoglycemia when compared to other drugs and weight reduction observed in dipeptidyl peptidase inhibitors.

Download Full-text

ESTIMATION OF SERUM FERRITIN LEVELS IN TYPE 2 DIABETIC PATIENTS AND ITS RELATION WITH HbA1C LEVEL.

International Journal of Medical and Biomedical Studies ◽

10.32553/ijmbs.v3i8.456 ◽

2019 ◽

Vol 3 (8) ◽

Author(s):

Shah Namrata Vinubhai ◽

Pardeep Agarwal ◽

Bushra Fiza ◽

Ramkishan Jat

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Blood Sugar ◽

Serum Ferritin ◽

Inflammatory Marker ◽

Control Group ◽

Diabetic Patients ◽

Positive Correlation

Background: Serum ferritin is known as an index for body iron stores also as an inflammatory marker and it is influenced by several disease. We were looking for a correlation between HbA1c and S. Ferritin in type 2 DM. Methodology: The present study a total of 150 participants were enrolled of which 100 were confirmed cases of Type 2 Diabetes Mellitus and rest 50 age and sex matched healthy subjects constituted the control group. All were screened for HbA1c, Fasting blood sugar, Post prandial blood sugar and S.Ferritin. Results: A highly significant variation and positive correlation was observed with respect to S.Ferritin and HbA1c levels. Mean S.Ferritin was high in the subgroup with poor glycemic control. Conclusion: The fasting, post prandial sugar levels, HbA1c and S.Ferritin were significantly higher in the diabetic subjects. This study shows a positive correlation between HbA1c and S. Ferritin levels. So we can conclude that in diabetic patients S. Ferritin may serve as an independent marker of poor glycemic and metabolic control. Keywords: Serum ferritin, Type 2 Diabetes Mellitus, HbA1c.

Download Full-text

Evaluation of serum adropin and irisin levels and its association with anthropometric obesity indices and biochemical parameters in Type 2 diabetic patients

Nutrition and Healthy Aging ◽

10.3233/nha-200110 ◽

2021 ◽

pp. 1-8

Author(s):

Foad Alzoughool ◽

Huda Al Hourani ◽

Manar Atoum ◽

Sajedah Bateineh ◽

Hanan Alsheikh ◽

...

Keyword(s):

Negative Correlation ◽

Biochemical Parameters ◽

Significant Positive Correlation ◽

Glycosylated Hemoglobin ◽

Significant Negative Correlation ◽

Diabetic Patients ◽

Positive Correlation ◽

Obesity Indices ◽

Group Serum

BACKGROUND/AIM: The newly described proteins adropin and irisin are a highly conserved polypeptide that plays essential roles in metabolic and energy homeostasis, insulin resistance, and fat browning. The aim of this study is to evaluate the circulating levels of serum adropin and irisin in type 2 diabetes mellitus (T2DM) patients and also to elucidate possible relationships between serum adropin and irisin levels with anthropometric obesity indices and biochemical parameters. SUBJECTS AND METHODS: Single-center prospective observational study included 90 T2DM patients referred to the diabetes outpatient clinic. Height, weight, and waist circumference (WC) were measured. Body mass index (BMI) and waist to height ratio (WHtR) were calculated. Fasting blood glucose, glycosylated hemoglobin, serum lipids, creatinine, urea, and blood urea nitrogen were evaluated. Estimated glomerular filtration rate (GFR) was calculated, serum adropin and irisin were evaluated. RESULTS: The results showed a significant positive correlation between adropin and irisin in females but not in males (r = 0.311; P = 0.042). In males’ group, serum adropin levels showed significant negative correlation with serum glucose (–0.423, P = < 0.05), HbA1C (–0.364, P = < 0.05), and GFR (–0.355, P = < 0.05). In contrast, creatinine was showed a significant positive correlation with adropin in males (0.381, P = < 0.05). In females’ group, adropin showed a significant negative correlation with weight (–0.371, P = < 0.05), BMI (–0.349, P = < 0.05), WC (–0.402, P = < 0.01), and WHtR (–0.398, P = < 0.01). Contrary, in males’ group, serum irisin levels showed significant positive correlation with weight (0.338, P = < 0.05), BMI (0.332, P = < 0.05), WC (0.409, P = < 0.01), and WHtR (0.432, P = < 0.01). CONCLUSION: This study demonstrated that, in T2DM patients, circulating serum adrpoin correlated negatively with anthropometric obesity indices of obesity in females, while serum irisin was positively correlated with anthropometric obesity indices of obesity in males.

Download Full-text

Evaluating the Effect of Knowledge, Attitude, and Practice on Self-Management in Type 2 Diabetic Patients on Dialysis

Journal of Diabetes Research ◽

10.1155/2016/3730875 ◽

2016 ◽

Vol 2016 ◽

pp. 1-7 ◽

Cited By ~ 12

Author(s):

Shima Ghannadi ◽

Atieh Amouzegar ◽

Parisa Amiri ◽

Ronak Karbalaeifar ◽

Zhale Tahmasebinejad ◽

...

Keyword(s):

Quality Of Life ◽

Microvascular Complications ◽

Glycosylated Hemoglobin ◽

Self Care ◽

Self Management ◽

Diabetic Patients ◽

Attitude And Practice ◽

Knowledge Attitude And Practice

Background.Type 2 diabetes is an increasingly common condition with several preventable microvascular complications such as kidney damage. Nephropathy is expensive to manage, especially as hospital dialysis treatment. Improving patients’ knowledge, attitude, and practice (KAP) toward their condition can achieve better control, delay complications, and improve their quality of life. This study evaluated the KAP and self-care behaviors of diabetic patients on dialysis and variables that affect it.Methods.This cross-sectional study was conducted at Shahid Beheshti academic hospitals of Tehran, Iran. Face-to-face interviews were held to fill five validated questionnaires: three evaluating KAP, one evaluating self-management, and one evaluating quality of life.Result.117 diabetic patients on hemodialysis (42 females) with mean (SD) age of68.70±9.26years were enrolled in the survey. The scores for patient’s KAP, self-care, and quality of life were59.90±11.23,44.27±8.35,45.06±12.87,46.21±10.23, and26.85±13.23, respectively. There was significant negative correlation between patients’ knowledge and attitude with their glycosylated hemoglobin level and their fasting blood sugar. There was significant correlation between patients’ knowledge and practice with their self-care activities.Conclusion.The present study suggests that patients’ KAP scores have a practical effect upon self-care behavior. This highlights the needs for effective diabetes education programs in developing countries like Iran.

Download Full-text

Evaluation of the alterations in the serum blood sugar level, the activity of AST and ALT enzymes of diabetes mellitus type 2 in Iraqi women patients

Research Journal of Biotechnology ◽

10.25303/168rjbt9821 ◽

2021 ◽

Vol 16 (8) ◽

pp. 98-102

Author(s):

Hashim Abdul Razzaq Iman ◽

Hussein Murtadha Jinan

Keyword(s):

Diabetes Mellitus ◽

Blood Sugar ◽

Diabetes Mellitus Type 2 ◽

Correlation Factor ◽

Diabetes Mellitus Type ◽

Fasting Blood Sugar ◽

Diabetic Patients ◽

Cell Dysfunction ◽

Iraqi Women

Diabetes mellitus type 2 (T2DM) results from beta cell dysfunction or reduced action of insulin responsive. The objective of this study was to examine the relevance between blood sugar, the activity of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in fasting women diabetic patients in different durations. A total of sixty-eight women were divided into three groups: first a healthy group – non-diabetic (twenty-six women), second and third groups (twenty-one) were diabetic patients of age 35 – 50 and 51 – 69 years respectively. Serum fasting blood sugar was significantly (P < 0.05) elevated to 181.60 mg/dl in female patients with 35 – 50 years. The same effect happened in activity of AST to 32.91 u/L in 51 – 69 years and ALT was 28.43 u/L in 35 – 50 years. No significant differences were found between the aged and fasting blood sugar, AST and ALT in diabetic patients. The correlation factor (r) between fasting blood sugar and the activity of ALT was highly significant.

Download Full-text

Serum High Lipoprotein(a) Levels in Patients with Type 2 Diabetes May Be an Independent Risk Factor for Hypertension

Journal of Clinical Medicine Research ◽

10.32629/jcmr.v2i2.347 ◽

2021 ◽

Vol 2 (2) ◽

Author(s):

Lingfen Zeng ◽

Jieming Sun ◽

Ming Cui

Keyword(s):

Blood Pressure ◽

Type 2 Diabetes ◽

Risk Factor ◽

Independent Risk Factor ◽

Glycosylated Hemoglobin ◽

Serum Triglyceride ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Lipoprotein A

Objective — To investigate whether serum lipoprotein(a) [Lp(a)] is an independent risk factor for abnormal blood pressure in patients with type 2 diabetes mellitus. Method — Analyzed data collected from diabetes patients and epidemiological survey from January 1,2020 to May 01,2021, with hypertension as a dependent variable, metabolic index such as glycosylated hemoglobin, serum total cholesterol, serum triglyceride and Lp(a) were independent variables, established logistic regression equation, analyze the influence of their variables on dependent variables. Results — The OR value of Lp(a) is 1.020, 95% confidence intervals (1.006, 1.035), p 0.006; The OR value of age is 1.073, 95% confidence interval (1.028, 1.119); and OR of the remaining parameters were tested no statistically different, p>0.05. Conclusions — The abnormal elevated Lp(a) level in the serum of type 2 diabetic patients may be related to the occurrence of hypertension. For patients with high Lp(a), Monitoring blood pressure may help to better detect and diagnose hypertension. At the same time, it is suggested that reducing serum Lp(a) level may reduce the risk of hypertension.

Download Full-text

Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia

10.21203/rs.2.20116/v2 ◽

2020 ◽

Author(s):

Xiaomeng Sun ◽

Jia Liu ◽

Guang Wang

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Treatment Group ◽

Glycosylated Hemoglobin ◽

Fasting Blood Glucose ◽

Control Group ◽

Diabetic Patients ◽

Fenofibrate Treatment

Abstract Background: This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia. Methods: Type 2 diabetic patients (56) with microalbuminuria and hypertriglyceridemia aged 30 to 75 were randomly divided into the fenofibrate treatment group(n=28) and the control group (n=28) for 180 days. Urinary microalbumin /creatinine ratio (UACR) and other metabolic parameters were compared at baseline, during treatment and after treatment. Results: After 180 days, the reduction of levels of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) in two groups were no differences. In treatment group, uric acid (UA) (296.42 ± 56.41 vs 372.46 ± 72.78), triglyceride (TG) [1.51(1.17, 2.06) vs 3.04(2.21, 3.29)], and UACR [36.45 (15.78,102.41) vs 129.00 (53.00, 226.25)] were significantly decreased compared with the baseline. The high-density lipoprotein cholesterol (HDL-C) levels were significantly increased (1.22 ± 0.26 vs 1.09 ± 0.24) compared with the baseline. The decrease in UACR [-44.05(-179.47, -12.16) vs -8.15(-59.69, 41.94)]in treatment group was significantly higher compared with the control group. The decrease in UACR was positively associated with the decreases in TG ( r = 0.447, P = 0.042) and UA ( r = 0.478, P = 0.024) after fenofibrate treatment. Conclusion: In the patients with hypertriglyceridemia and type 2 diabetes mellitus, fenofibrate can improve microalbuminuria and do not increase the deterioration of glomerular filtration rate

Download Full-text

Low-Glycemic-Index Sugar in Type 2 Diabetic Patients: A Randomized Controlled Study

10.21203/rs.3.rs-685948/v1 ◽

2021 ◽

Author(s):

Damien Steciuk ◽

Samia Mahmood Hafez Amir ◽

Muzzammil Hosenally ◽

Aroushini Goorapah

Keyword(s):

Blood Sugar ◽

Glycemic Index ◽

Glucose Monitoring ◽

Controlled Study ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Sugar Levels ◽

Type 2 Diabetic ◽

Low Glycemic Index

Abstract Background and Objectives: There is a need to re assess the value of low-GI food and its specific components. The effect of one of them, namely low-glycemic-index sugar, is unclear, as its impact is usually confounded when reported in the literature. This study attempts to breach this gap, shedding light on its effect in type 2 diabetic patients and evaluate if it could be considered as part of a dietary plan.Subjects and Methods: The blood sugar level of twenty (20) type 2 diabetics was monitored using a Continuous Glucose Monitoring system during two phases; firstly, an initial period of 5 days, whereby all the included patients were taking their usual dietary meals. Subjects were then randomized into two groups of equal size before embarking on a second phase; 10 subjects were instructed to eat prepared, portioned and delivered meals, the difference for the second group being that low-GI sugar was used for the preparation. Results: Compared to baseline (day 1), blood sugar dropped by 18% for the group with low-GI sugar and 13% for those who consumed sugar with a normal-GI. The variation in sugar levels was also more contained in the interventional group. A by-product of the study design shows that constant glucose monitoring could raise awareness, and may foster reduction in blood sugar levels. Portioned food was capable of reducing blood sugar levels, with elevated levels of compliance just after start. Conclusions: Even though the ultimate aim is to reduce sugar consumption by diabetic patients, the intake of a low-GI sugar seems to be less harmful than normal sugar. Compared to using normal sugar for the preparation of portioned foods, the use of a low-GI sugar is encouraged as part of a wider plan for the management of diabetic patients.

Download Full-text

Study of metformin in diabetes mellitus with stage 3 and 4 chronic kidney disease

Journal of Diabetes and Endocrine Association of Nepal ◽

10.3126/jdean.v4i1.30073 ◽

2020 ◽

Vol 4 (1) ◽

pp. 21-28

Author(s):

D. Peeyush ◽

M. Lamsal ◽

R. Maskey ◽

S.K. Sharma

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Lactic Acidosis ◽

Blood Sugar ◽

Case Reports ◽

Glycosylated Hemoglobin ◽

Diabetic Patients ◽

Insulin Group ◽

Metformin Group ◽

Ckd Stage

Background: Chronic Kidney Disease is one of the major complications of Diabetic patients. Cardiovascular mortality increases in patient with diabetes and more so with diabetic CKD. Clinician treating diabetic CKD finds option limited as metformin is considered contraindicated when serum creatinine is greater than 1.5 mg/dl in males and greater than 1.4 mg/dl in females. The primary aim of the study is to evaluate the efficacy of metformin in terms of glycemic control in patient with diabetic stage 3 and 4 CKD. Methods: This is Randomised open labelled clinical trial done in the Department of Internal Medicine, B. P. Koirala Institute of Health Sciences, Dharan, Nepal. Primary end point were glycemic status at 6 months as defined by with fasting, post prandial blood sugar, glycosylated hemoglobin in comparison to baseline. Results: Altogether 73 diabetic patients with diabetic CKD stage 3 and 4 were included in the study. 41 patients were included in insulin group and 32 patients in metformin group. In metformin group, the fasting and past prandial blood sugar declined progressively compared to insulin group, where fasting and post prandial blood sugar declined more rapidly. Conclusions: Metformin is found to be efficacious in diabetic CKD as it had already proved to be effective in diabetes without CKD. In this study metformin was not associated with lactic acidosis and the level of lactate with metformin treatment was similar to that of treatment with insulin. The vast majority of case reports relating metformin to lactic acidosis report at least one other disease/illness that could result in lactic acidosis. Despite increasing disregard of contraindications to metformin by physicians, the incidence of lactic acidosis has not increased, as does the result of this study. So metformin may be safe even in patients with diabetic CKD stage 3 and 4.

Download Full-text